These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
392 related articles for article (PubMed ID: 31518182)
1. Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement. Sears CR; Peikert T; Possick JD; Naidoo J; Nishino M; Patel SP; Camus P; Gaga M; Garon EB; Gould MK; Limper AH; Montgrain PR; Travis WD; Rivera MP Am J Respir Crit Care Med; 2019 Sep; 200(6):e31-e43. PubMed ID: 31518182 [No Abstract] [Full Text] [Related]
2. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. Cho JY; Kim J; Lee JS; Kim YJ; Kim SH; Lee YJ; Cho YJ; Yoon HI; Lee JH; Lee CT; Park JS Lung Cancer; 2018 Nov; 125():150-156. PubMed ID: 30429014 [TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor-related chronic pneumonitis: a case report and literature review. Yuan-Di Wang ; Yuan S; Wen C; Ji Z; Xiang B; Wang B; Zhang Z Immunotherapy; 2023 Oct; 15(14):1117-1123. PubMed ID: 37431609 [TBL] [Abstract][Full Text] [Related]
12. Evaluating Pneumonitis Incidence in Patients with Non-small Cell Lung Cancer Treated with Immunotherapy and/or Chemotherapy Using Real-world and Clinical Trial Data. Liu Q; Zhang C; Huang Y; Huang R; Huang SM; Larkins E; Stapleford L; Rivera DR; Kluetz PG; Wang S; Zhu H; Weese J; Cromartie E; Teka M; Walters S; Wolf F; Brown TD Cancer Res Commun; 2023 Feb; 3(2):258-266. PubMed ID: 36860658 [TBL] [Abstract][Full Text] [Related]
13. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report. Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923 [TBL] [Abstract][Full Text] [Related]
14. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. Zhai X; Zhang J; Tian Y; Li J; Jing W; Guo H; Zhu H Cancer Biol Med; 2020 Aug; 17(3):599-611. PubMed ID: 32944393 [TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Suresh K; Naidoo J; Lin CT; Danoff S Chest; 2018 Dec; 154(6):1416-1423. PubMed ID: 30189190 [TBL] [Abstract][Full Text] [Related]
16. Pulmonary toxicity of systemic lung cancer therapy. Long K; Suresh K Respirology; 2020 Nov; 25 Suppl 2():72-79. PubMed ID: 32729207 [TBL] [Abstract][Full Text] [Related]
19. The Risk Factors Associated with Immune Checkpoint Inhibitor-Related Pneumonitis. Asada M; Mikami T; Niimura T; Zamami Y; Uesawa Y; Chuma M; Ishizawa K Oncology; 2021; 99(4):256-259. PubMed ID: 33477139 [TBL] [Abstract][Full Text] [Related]
20. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis. Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]